

5 November 2025

Nanosonics to commence \$20 million on-market share buy-back program

Nanosonics Limited (ASX: NAN), a global leader in infection prevention, today announces an on-market share buy-back of up to \$20 million in FY26, as part of its disciplined capital management strategy.

The buy-back reflects the Company's strong financial position, consistent cash generation and confidence in its long-term growth outlook.

"Nanosonics' business model is built on a solid foundation of capital revenue from trophon® device sales and growing recurring revenue from consumables and services," said CEO and President, Michael Kavanagh.

"With no debt and a history of predictable cash flows, we've invested decisively in our next growth horizon, developing and launching trophon3 and trophon2 Plus, and the development and FDA De Novo approval of the CORIS system. These innovations not only strengthen our leadership in infection prevention but also open significant new opportunities for continued growth."

"The Board is confident Nanosonics has sufficient cash reserves to fund its strategic initiatives, including the continued growth of the trophon business, the controlled market release and broader commercialisation of CORIS, and pursuing selective potential bolt-on acquisitions. The buy-back is a reflection of that confidence and our commitment to delivering long-term value to shareholders," he concluded.

Nanosonics remains committed to a balanced capital management approach, maintaining a strong balance sheet while investing for growth and returning capital to shareholders in a way that reflects the Company's strong fundamentals and future potential.

The buy-back is expected to commence following the Company's required notice to ASIC, and will be conducted in the ordinary course of trading, outside designated blackout periods. The program may be varied, suspended, or terminated at any time depending on market conditions, share price, operational performance, and alternative capital deployment opportunities.

The buy-back will be conducted under the '10/12 limit' permitted by Section 257B(4) of the Corporations Act 2001 and does not require shareholder approval. Shares purchased will be cancelled, reducing the total number of shares on issue.

For more information, please contact:

Catherine Strong, Head of Investor Relations and Corporate Communications
+61 (0)406 759 268, c.strong@nanosonics.com

Authorised by the Board of Directors of Nanosonics Limited.

trophon® and CORIS® are registered trade marks of Nanosonics Limited.